Toll Free: 1-888-928-9744

Systemic Sclerosis (Scleroderma) Global Clinical Trials Review, H1, 2016

Published: Mar 31, 2016 | Pages: 190 | Publisher: GlobalData | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Systemic Sclerosis (Scleroderma) Global Clinical Trials Review, H1, 2016

Summary

GlobalData's clinical trial report, 
 Table of Contents
1 Table of Contents 2 List of Tables 3 List of Figures 4 Report Guidance 5 Clinical Trials by Region 6 Clinical Trials and Average Enrollment by Country 7 Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10 Top Five Countries Contributing to Clinical Trials in Europe 11 Top Countries Contributing to Clinical Trials in North America 12 Top Countries Contributing to Clinical Trials in Middle East and Africa 13 Top Countries Contributing to Clinical Trials in Central and South America 14 Clinical Trials by G7 Countries: Proportion of Systemic Sclerosis (Scleroderma) to Immunology Clinical Trials 15 Clinical Trials by Phase in G7 Countries 17 Clinical Trials in G7 Countries by Trial Status 18 Clinical Trials by E7 Countries: Proportion of Systemic Sclerosis (Scleroderma) to Immunology Clinical Trials 19 Clinical Trials by Phase in E7 Countries 20 Clinical Trials in E7 Countries by Trial Status 21 Clinical Trials by Phase 22 In Progress Trials by Phase 23 Clinical Trials by Trial Status 24 Clinical Trials by End Point Status 25 Subjects Recruited Over a Period of Time 26 Clinical Trials by Sponsor Type 27 Prominent Sponsors 28 Top Companies Participating in Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials 29 Prominent Drugs 31 Latest Clinical Trials News on Systemic Sclerosis (Scleroderma) 32 Mar 24, 2016: Cytori provides Update on Its U.S. Phase III Scleroderma Trial 32 Mar 15, 2016: ProMetic announces the addition of scleroderma to PBI-4050 targeted indications 32 Feb 25, 2016: Inventiva rewarded for its innovative approach with IVA337 at the 4th Systemic Sclerosis World Congress 33 Feb 22, 2016: Data Reports Sustained Benefit at Two Years with Single Administration Cytori Cell Therapy for Scleroderma 33 Feb 10, 2016: Scleroderma Two Year Data to be Presented at the 4th Systemic Sclerosis World Congress 34 Jan 28, 2016: IVA337 delivers significant therapeutic advances in fibrosis, a major public health challenge 34 Jan 25, 2016: Cytori Update on Its U.S. Phase III Scleroderma Trial 35 Clinical Trial Profile Snapshots 36 Appendix 187 Abbreviations 187 Definitions 187 Research Methodology 188 Secondary Research 188 About GlobalData 189 Contact Us 189 Disclaimer 189 Source 190
List of Tables
Systemic Sclerosis (Scleroderma) Therapeutics, Global, Clinical Trials by Region, 2016* 6 Systemic Sclerosis (Scleroderma) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8 Systemic Sclerosis (Scleroderma) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9 Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 10 Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 11 Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, North America, Top Countries, 2016* 12 Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 13 Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 14 Proportion of Systemic Sclerosis (Scleroderma) to Immunology Clinical Trials, G7 Countries (%), 2016* 16 Systemic Sclerosis (Scleroderma) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 17 Systemic Sclerosis (Scleroderma) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 18 Proportion of Systemic Sclerosis (Scleroderma) to Immunology Clinical Trials, E7 Countries (%), 2016* 19 Systemic Sclerosis (Scleroderma) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 20 Systemic Sclerosis (Scleroderma) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 21 Systemic Sclerosis (Scleroderma) Therapeutics, Global, Clinical Trials by Phase, 2016* 22 Systemic Sclerosis (Scleroderma) Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 23 Systemic Sclerosis (Scleroderma) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 24 Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 25 Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 26 Systemic Sclerosis (Scleroderma) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 27 Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 28 Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 30 Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 31


List of Figures
Systemic Sclerosis (Scleroderma) Therapeutics, Global, Clinical Trials by Region (%), 2016* 6 Systemic Sclerosis (Scleroderma) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7 Systemic Sclerosis (Scleroderma) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9 Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 10 Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 11 Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 12 Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 13 Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016* 14 Proportion of Systemic Sclerosis (Scleroderma) to Immunology Clinical Trials, G7 Countries (%), 2016* 15 Systemic Sclerosis (Scleroderma) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 17 Systemic Sclerosis (Scleroderma) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 18 Proportion of Systemic Sclerosis (Scleroderma) to Immunology Clinical Trials, E7 Countries (%), 2016* 19 Systemic Sclerosis (Scleroderma) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 20 Systemic Sclerosis (Scleroderma) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 21 Systemic Sclerosis (Scleroderma) Therapeutics, Global, Clinical Trials by Phase (%), 2016* 22 Systemic Sclerosis (Scleroderma) Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 23 Systemic Sclerosis (Scleroderma) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 24 Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 25 Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 26 Systemic Sclerosis (Scleroderma) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 27 Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 28 Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 29 Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 31 GlobalData Methodology 188

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global non destructive testing equipment market is anticipated to reach USD 5.76 billion by 2022, as per a new research report by Radiant Insights, Inc. Stringent government safety initiatives for inspection and quality control across numerous indust

Read More...

Europe industrial air filtration market size is projected to reach USD 1,690.8 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing implementation in various industries such as metal, cement and food & beverages among ot

Read More...

Global intelligent transportation system (ITS) market is estimated to attain USD 38.68 billion by 2020, as per a new research report by Radiant Insights, Inc. Cost effectiveness along with escalating need for road safety is likely to boost global dem

Read More...

Global PP (Polypropylene) nonwoven fabric market size is anticipated to be valued at USD 30.6 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing usage of hygiene products such as incontinence products and baby diapers is

Read More...

Global FPGA market is anticipated to be valued at USD 9,882.5 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing demand for customized IC’s is expected to drive the demand. Customized IC’s helps manufacturers to mo

Read More...
Choose License Type
Single User - US $2500
Multi User - US $5000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify